GET THE APP

Characterisation of Adenovirus transcomplementationmediated gene | 864
Journal of Antivirals & Antiretrovirals

Journal of Antivirals & Antiretrovirals
Open Access

ISSN: 1948-5964

+44 1300 500008

Characterisation of Adenovirus transcomplementationmediated gene expression controlled by melanomaspecifi c TETP promoterg


International Conference and Exhibition on VIROLOGY

5-7 September 2011 Baltimore, USA

A. Curioni Fontecedro

Scientific Tracks Abstracts: JAA

Abstract :

Human adenoviruses (Ads) have substantial potential for clinical applications in cancer patients. Conditionally replicating adenoviruses (CRAds) include oncolytic adenoviruses in which expression of the immediate early viral transactivator protein E1A is controlled by a cancer cell-selective promoter. To enhance effi cacy, CRAds are further armed to contain therapeutic genes. Due to size constraints of the capsid geometry, the capacity for packaging transgenes into Ads is, however, limited. To overcome this limitation, the employment of E1A-deleted replication-defi cient viruses carrying therapeutic genes in combination with replication-competent CRAd vectors expressing E1A in trans has been proposed. Most transcomplementing studies involved transgene expressions from strong ubiquitous promoters, and thereby relied entirely on the cancer cell specifi city of the CRAd vector. We tested the trans-complementation of a CRAd and a replication-defi cient transgene vector containing the same cancer cell-selective promoter. We generated two vectors expressing IL-2 and CD40L from a bicistronic expression cassette under the control of the melanoma/melanocytespecifi c tyrosinase enhancer tyrosinase promoter (TETP). Th ese vectors gave rise to tightly controlled melanoma-specifi c transgene expression levels but the cancer cell-selective TETP did not give the expected enforceable transgene expression typically achieved in the Ad transcomplementing system. Reasons for this could include virus-mediated down regulation of limiting transcription factors, and/or competition for such factors by diff erent promoters and warrants further investigations.

Biography :

Dr. med. A. Curioni-Fontecedro has completed her medical studies in 2004 in the University of Rome Campus Biomedico and in 2005 received ther MD title from the University of Zurich and the University of Rome Campus Biomedico. She was scientifi c physician in the Laboratory of Tumor immunology of the Uniiversity Hospital of Zurich from 2005 to 2007. Since 2007 she is physician in the Department of Onology and Internal Medicine, leading and participating to research and clinical studies in the area of tumor immunology.

Top